BCM
TTOO

BlueCrest Capital Management’s T2 Biosystems, Inc TTOO Stock Holding History

BlueCrest Capital Management’s Portfolio TTOO Stock Details TTOO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3
Closed -$96K – 1901
2018
Q1 		$96K Sell
3
-2
-40% -$53.8K ﹤0.01% 1369
2017
Q4 		$98K Buy
+5
New +$103K ﹤0.01% 766

Other funds holding TTOO

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlueCrest Capital Management's TTOO Position: Q2 2018 in Review

BlueCrest Capital Management sold out of T2 Biosystems, Inc (TTOO) in Q2 2018, closing a stake of 3 shares — an estimated $96K sold.

BlueCrest Capital Management first reported a position in TTOO in Q4 2017 and held it in 2 quarters. The position peaked at $98K in Q4 2017. 89 funds tracked by Wall St. Rank hold TTOO as of Q2 2018.

  • BlueCrest Capital Management reported no remaining T2 Biosystems, Inc position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 3 T2 Biosystems, Inc shares in Q2 2018, an estimated $96K.
  • BlueCrest Capital Management first reported a position in T2 Biosystems, Inc in Q4 2017 and held it in 2 quarters.
  • BlueCrest Capital Management's T2 Biosystems, Inc position peaked at $98K in Q4 2017.
  • 89 funds tracked by Wall St. Rank held T2 Biosystems, Inc as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.